Abstract 341P
Background
Lean body mass and low muscle mass are associated with survival, quality of life (QOL), and tolerance to treatment in cancer patients. Most early breast cancer patients were reported in overweight and obese nutrition status. There is still limited data evaluating the relationship between muscle mass and QOL in breast cancer patients, especially in early stages. The aim of this study is to examine the relationship between muscle mass and QOL domain in breast cancer patients before underwent chemotherapy.
Methods
A total of 80 breast cancer patients were enrolled in this study. Women breast cancer patients before they underwent chemotherapy were included in this study. Skeletal muscle mass was measured by bioelectrical impedance analysis, and it was reported as the Skeletal Muscle Index (SMI). QoL was assessed using the EORTC-QLQ-C30. The correlation between SMI and QOL was evaluated using Pearson or Spearmen correlation test based on the normality data.
Results
The mean of age was 47.39+7.07 years old. The median of body mass index (BMI) was 23.15(7.86-47.26) kg/m2. The distribution of BMI for underweight, normo-weight, overweight and obese were 5(6.3%); 33(41.3%); 16(21.1%); and 26(32.6%), respectively. Most patients were in early breast cancer 71 of 80 (88.8%). The median of SMI was 5.72(1.91-12.35). The median of QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were 66.67(0-100); 93.33(0-133.33); 100(0-133.33); 83.33(33.33-100); 100(16.67-100); and 100(0-100), respectively. The correlation between SMI and QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were (r 0.194, p 0.085); (r 0.021, p 0.851); (r 0.009, p 0.939); (r 0.061, p 0.588); (r 0.280, p 0.012); and (r 0.078, p 0.490), respectively.
Conclusions
Almost all QOL domains of breast cancer patients before underwent chemotherapy showed good results. The relationship between muscle mass and QOL in breast cancer patients before underwent chemotherapy only showed in the cognitive domain. Further studies need to be done to evaluate the physical activity and protein consumption practice with QoL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session